Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

  • End date
    Oct 1, 2024
  • participants needed
  • sponsor
    University Medical Center Ho Chi Minh City (UMC)
Updated on 11 May 2022
tumor markers
gastric adenocarcinoma
cancer chemotherapy


This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy


Gastric cancer is the fourth most common cancer in Vietnam with high mortality rate. Patients at early stages undergo radical gastrectomy with curative intent, but the remaining tumor cells, termed as minimal residual disease (MRD), can later cause relapse. Conventional methods to monitor MRD such as imaging and blood tests for biomarkers such as CEA are not sensitive and specific enough. ctDNA has recently emerged as a promising noninvasive marker with high accuracy to monitor MRD and detect relapse in many cancers such as breast and colorectal cancers. However, its application in gastric cancer has not been extensively evaluated. Therefore, this study aims to use advanced NGS technologies to detect ctDNA in liquid biopsy as a biomarker to monitor MRD after radical gastrectomy.

Condition Gastric Cancer, ctDNA
Treatment ctDNA
Clinical Study IdentifierNCT05029869
SponsorUniversity Medical Center Ho Chi Minh City (UMC)
Last Modified on11 May 2022


Yes No Not Sure

Inclusion Criteria

Male or Female patients aged 18 years and older
Histologically proven primary gastric adenocarcinoma before surgery
Clinical stage is locally advanced cT2-4a any N and M0
In initial evaluation, patient can undergo radical gastrectomy and lymphadenectomy
No preoperative therapy, including chemotherapy and radiotherapy
No known cancer diagnosis within last five years
Signed informed consent

Exclusion Criteria

Gastrectomy cannot be achieved during operation due to metastasis
Patient fails to follow-up and provide postoperative samples
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note